profit from every $100 of sales.

CDT Equity
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
You pay $4.70 for every $1 of profit it makes in a year.
of earnings would pay off all its debt.
CDT Equity vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
CDT Equity | 4.7× · Cheap | ||
Vertex Pharmaceuticals | 34.5× · Expensive | ||
Regeneron Pharmaceuticals | 21.9× · Fair price | ||
Moderna | No profit yet | ||
CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads CDT Equity's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 4.7×
- –
- 0.06
- 0.1×
- 0.0×
- –
- 13.5×
- -108,031.0%
- 21.3%
- 0.0%
Profitability
- 36.9%
- 6.4%
- 2.4%
- 11.5%
- 0.9%
- -912.5%
- 2.6%
- 0.5%
- 1.6%
- 4.9%
Growth
- –
- –
- −84.5%
- –
- +1,519.2%
Financial health
- 13.5×
- 1.05
- 39.0%
- 3.3×
- 2.09
- 1.40
- 0.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
News
Update: Sliding Chipmakers Push US Equity Indexes Lower While Producer Prices Growth Below ForecastYahoo Finance · Nov 13, 2026Update: US Equity Indexes Shrug Off Turmoil at Nvidia as CEO Jensen Huang ResignsYahoo Finance · Nov 12, 2026Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Nvidia Stock RecoversYahoo Finance · Nov 11, 2026Update: US Equity Indexes Drop as Inflation Data Strengthens Case for Fed Rate IncreaseYahoo Finance · Nov 10, 2026Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid October Consumer Inflation ReportYahoo Finance · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about CDT Equity
Is CDT Equity a good stock to buy?
A business with weak numbers, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CDT Equity AI analysis
What does CDT Equity do?
CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL. It is in Biotechnology.
Does CDT Equity pay a dividend?
No. CDT Equity does not pay a dividend at the moment.
How has CDT Equity stock done over the past year?
Down 80.0% over the past twelve months, to $0.00. It traded between $0.00 and $0.02 and is 80.0% below its high.
Who are CDT Equity's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with CDT Equity's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.



